Coagulation Self-testing to 2020
|出版商||Greystone Research Associates||商品編碼||201015|
The size and future potential of the coagulation self-testing market has been evolving over the past 24 months as two competing forces work to inject uncertainty into future demand. Demographic and incidence data indicate a definite upward trend in the clinical and managed care demand for anticoagulation therapeutics. But the commercialization of novel oral anticoagulants (NOACs) -a new class of drugs that does not require routine coagulation monitoring - will work to reduce demand for coagulation self-testing. The result will be a muddled global market where demand among countries and regions will vary based on individual market factors. To minimize risk and fully engage addressable markets, participants must commit to a comprehensive understanding of the key markets in which they currently, or plan to, compete.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-testing and management. In this environment, healthcare sector participants have come to realize that commercial success no longer depends solely on the product itself but also on achieving a consumer-compatible form of packaging and operation.